Planned phase I trial of a sustained-release formulation of sGC 1061 for treatment of Alzheimer's disease and age-related cognitive impairment.
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2012
At a glance
- Drugs SGC 1061 (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Adverse reactions; Pharmacokinetics
- 18 Jul 2012 New trial record